MX9804343A - Aplicacion dirigida de dosificaciones de agentes medicinales y terapeuticos y otros glicosaminoglicanos (gags). - Google Patents

Aplicacion dirigida de dosificaciones de agentes medicinales y terapeuticos y otros glicosaminoglicanos (gags).

Info

Publication number
MX9804343A
MX9804343A MX9804343A MX9804343A MX9804343A MX 9804343 A MX9804343 A MX 9804343A MX 9804343 A MX9804343 A MX 9804343A MX 9804343 A MX9804343 A MX 9804343A MX 9804343 A MX9804343 A MX 9804343A
Authority
MX
Mexico
Prior art keywords
agent
liver
medicine
receptors
binding
Prior art date
Application number
MX9804343A
Other languages
English (en)
Inventor
Stefan Gustafson
Original Assignee
Hyal Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002164260A external-priority patent/CA2164260C/en
Priority claimed from CA 2173037 external-priority patent/CA2173037A1/en
Application filed by Hyal Pharma Corp filed Critical Hyal Pharma Corp
Publication of MX9804343A publication Critical patent/MX9804343A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Se proporciona un método para el tratamiento de una enfermedad o condicion en un ser humano que pueda ser tratado con un agente medicinal y/o terapéutico, el cual pueda ser transportado por agente hasta el sitio que necesite tratamiento en el cuerpo, y cuyo agente también pueda transportar el agente medicinal y/o terapéutico hasta el hígado (mediante, por ejemplo, la fijacion del agente de transporte a los receptores del hígado), el cual comprende: (a) administrar una cantidad no toxica efectiva de un primer agente que no se fija a los receptores en el sitio que necesite tratamiento, sino que se fije con los receptores del hígado, "regulando hacia abajo" de esta manera el hígado; y (b) posteriormente, administrar una cantidad no toxica efectiva de un agente medicinal y/o terapéutico, y una cantidad efectiva de un segundo agente que sea un agente de transporte, y que sea un agente diferente del primer agente, que se fije al sitio que necesite tratamiento, y que sea capaz de fijarse a los sitios del hígado sino se hubiera "regulado hacia abajo" el hígado, de tal manera que se haya reducido sustancialmente su capacidad de fijacion para el segundo agente mediante la recuperacion por parte del hígado del primer agente administrado de acuerdo con el subpárrafo (a), por ejemplo, mediante la fijacion con los receptores eliminadores del hígado.
MX9804343A 1995-12-01 1998-06-01 Aplicacion dirigida de dosificaciones de agentes medicinales y terapeuticos y otros glicosaminoglicanos (gags). MX9804343A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002164260A CA2164260C (en) 1995-12-01 1995-12-01 Targeting of dosages of medicines and therapeutic agents
CA 2173037 CA2173037A1 (en) 1996-03-29 1996-03-29 Targeting of dosages of medicines and therapeutic agents and other glycosaminoglycans (gags)

Publications (1)

Publication Number Publication Date
MX9804343A true MX9804343A (es) 1998-09-30

Family

ID=25678243

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9804343A MX9804343A (es) 1995-12-01 1998-06-01 Aplicacion dirigida de dosificaciones de agentes medicinales y terapeuticos y otros glicosaminoglicanos (gags).

Country Status (11)

Country Link
EP (1) EP0869798A1 (es)
JP (1) JP2000513707A (es)
KR (1) KR19990071628A (es)
AU (1) AU727001B2 (es)
BR (1) BR9611671A (es)
HU (1) HUP9901935A3 (es)
IL (1) IL124647A0 (es)
MX (1) MX9804343A (es)
NO (1) NO982441L (es)
PL (1) PL326970A1 (es)
WO (1) WO1997020564A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPD940054A1 (it) * 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
CN100374163C (zh) 1999-01-13 2008-03-12 阿尔凯米亚肿瘤学私人有限公司 增强药物功效的组合物
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
CN103784960A (zh) * 2005-07-27 2014-05-14 阿尔卡米亚肿瘤学股份有限公司 使用乙酰透明质酸的治疗方案
CA2621279C (en) 2005-09-07 2016-06-14 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
AUPM714794A0 (en) * 1994-07-29 1994-08-18 International Fluid Separation Pty Limited Separation apparatus and method
JPH10504828A (ja) * 1994-08-30 1998-05-12 ハイアル ファーマスティカル コーポレイション 細胞活性調整のためのヒアルロン酸およびその誘導体

Also Published As

Publication number Publication date
EP0869798A1 (en) 1998-10-14
BR9611671A (pt) 1999-12-28
PL326970A1 (en) 1998-11-09
AU7687896A (en) 1997-06-27
NO982441D0 (no) 1998-05-28
HUP9901935A3 (en) 2001-04-28
HUP9901935A2 (hu) 1999-11-29
IL124647A0 (en) 1998-12-06
JP2000513707A (ja) 2000-10-17
WO1997020564A1 (en) 1997-06-12
KR19990071628A (ko) 1999-09-27
NO982441L (no) 1998-05-28
AU727001B2 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
EP0831832A4 (en) METHODS FOR CONTROLLING INFECTIOUS DISEASES USING DICATIONIC BIS-BENZIMIDAZOLES
YU77000A (sh) Primena peg-ifn-alfa i ribavirina za lečenje hroničnog hepatitisa c
CA2285203A1 (en) Compositions containing capsaicin or capsaicin analogues and a local anesthetic
NZ296893A (en) Treatment/prevention of adverse reactions to skin irritants by administration of a loop diuretic optionally in conjunction with a mast cell degranulator or a glucocorticosteroid;transdermal delivery device
AU1877992A (en) Linsidomin for treating erectile dysfunctions
PL309596A1 (en) Application of anticonvulsant agents in treating parkinson disease and parkinsonian syndromes
HUT71224A (en) Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and an s-phase or m-phase specific antineoplastic agent
CA2150185A1 (en) Pharmaceutical composition for the treatment of stoma-peripheral inflammation
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
MX9804343A (es) Aplicacion dirigida de dosificaciones de agentes medicinales y terapeuticos y otros glicosaminoglicanos (gags).
MY124465A (en) Reduction of infarct volume using citicoline
KR960030947A (ko) src SH2 특이성 화합물의 골흡수 질환 치료 용도
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
EP1003370A4 (en) METHOD FOR INCREASING MAGNESIUM ABSORPTION AND PREVENTING ARTHEROSCLEROSIS
HK1015692A1 (en) Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections
BR9612355A (pt) Agentes de ligação com os receptores de ácido hialurÈnico e o uso destes.
CA2164260A1 (en) Targeting of dosages of medicines and therapeutic agents
WO1995005364A3 (en) Inhibitors of biogenic amine transporters
KR900017599A (ko) 종양 치료용 약학 조성물
IL129267A (en) Pharmaceutical compositions comprising histamine and/or serotonin for treatment of urinary incontinence
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
AWAZU et al. Primary Experience in Treatment for Respiratory Diseases with Oriental Medicine
CO5251402A1 (es) Metodo pra tratar el mal de parkinson a traves de la administracion de (-)-5-ceto-2-n,n-di-n-propilamino tetrahidrotetralina
BR9804054A (pt) Método de terapia de depósito de antiprogestina.
RU94020918A (ru) Способ лечения опсоменореи